231 related articles for article (PubMed ID: 37493758)
41. Where are we with the benefit-risk ratio of JAK inhibitors in rheumatoid arthritis?
Avouac J
Joint Bone Spine; 2022 Nov; 89(6):105454. PubMed ID: 35964885
[No Abstract] [Full Text] [Related]
42. Immune hallmarks of rheumatoid arthritis management: A brief review.
Fonseca Peixoto R; Ewerton Maia Rodrigues C; Henrique de Sousa Palmeira P; Cézar Comberlang Queiroz Davis Dos Santos F; Keesen de Souza Lima T; de Sousa Braz A
Cytokine; 2022 Oct; 158():156007. PubMed ID: 35985174
[TBL] [Abstract][Full Text] [Related]
43. Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis.
Riley TR; George MD
RMD Open; 2021 Feb; 7(1):. PubMed ID: 33597206
[TBL] [Abstract][Full Text] [Related]
44. Treatment patterns in patients with rheumatoid arthritis initiating a JAK inhibitor or a TNF inhibitor based on retail pharmacies drug-dispensing data.
Sambourg J; Gouverneur A; Bardoulat I; Schaeverbeke T; Truchetet ME; Maravic M
Joint Bone Spine; 2023 Dec; 90(6):105629. PubMed ID: 37634873
[No Abstract] [Full Text] [Related]
45. Which should be first: biologic DMARDs or Janus kinase inhibitors?
Koike T
Rheumatology (Oxford); 2023 May; 62(5):1738-1739. PubMed ID: 36355459
[No Abstract] [Full Text] [Related]
46. Biologics-based therapy for the treatment of rheumatoid arthritis.
Scott DL
Clin Pharmacol Ther; 2012 Jan; 91(1):30-43. PubMed ID: 22166850
[TBL] [Abstract][Full Text] [Related]
47. Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors.
Rivellese F; Lobasso A; Barbieri L; Liccardo B; de Paulis A; Rossi FW
Curr Med Chem; 2019; 26(16):2823-2843. PubMed ID: 29424301
[TBL] [Abstract][Full Text] [Related]
48. State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
El Jammal T; Sève P; Gerfaud-Valentin M; Jamilloux Y
Expert Opin Pharmacother; 2021 Feb; 22(2):205-218. PubMed ID: 32967471
[TBL] [Abstract][Full Text] [Related]
49. Janus kinase inhibitors for rheumatoid arthritis.
Yamaoka K
Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
[TBL] [Abstract][Full Text] [Related]
50. Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review.
Doria A; Zavaglia D
Clin Exp Rheumatol; 2019; 37(5):862-871. PubMed ID: 31376250
[TBL] [Abstract][Full Text] [Related]
51. Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors.
Jovani V; Calabuig I; Peral-Garrido ML; Tovar-Sugrañes E; López-González MD; Bernabeu P; Martínez A; Esteve-Vives J; León-Ramírez JM; Moreno-Perez O; Boix V; Gil J; Merino E; Vela P; Andrés M
Ann Rheum Dis; 2022 Jul; 81(7):e131. PubMed ID: 32586922
[No Abstract] [Full Text] [Related]
52. Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.
Meyer A; Wittekind PS; Kotschenreuther K; Schiller J; von Tresckow J; Haak TH; Kofler DM
Ann Rheum Dis; 2021 Dec; 80(12):e196. PubMed ID: 31744827
[No Abstract] [Full Text] [Related]
53. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
Iwata S; Tanaka Y
Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
[TBL] [Abstract][Full Text] [Related]
54. Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study.
Song YJ; Cho SK; Kim H; Kim HW; Nam E; Bae SC; Yoo DH; Sung YK
J Korean Med Sci; 2021 Mar; 36(10):e70. PubMed ID: 33724737
[TBL] [Abstract][Full Text] [Related]
55. JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
Kerrigan SA; McInnes IB
Curr Rheumatol Rep; 2018 Nov; 20(12):83. PubMed ID: 30406861
[TBL] [Abstract][Full Text] [Related]
56. Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis.
Combe B
Joint Bone Spine; 2006 Dec; 73(6):587-90. PubMed ID: 17071123
[No Abstract] [Full Text] [Related]
57. [Biologicals and small molecules for rheumatoid arthritis].
Blüml S
Z Rheumatol; 2020 Apr; 79(3):223-231. PubMed ID: 32179964
[TBL] [Abstract][Full Text] [Related]
58. JAK inhibitors for the treatment of rheumatoid arthritis.
Morinobu A
Immunol Med; 2020 Dec; 43(4):148-155. PubMed ID: 32501149
[TBL] [Abstract][Full Text] [Related]
59. Expanded table: some biologic agents and JAK inhibitors for RA.
Med Lett Drugs Ther; 2018 Jul; 60(1552):e130-e134. PubMed ID: 30044768
[No Abstract] [Full Text] [Related]
60. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
